About OncoSynergy
OncoSynergy is a company based in San Francisco (United States) founded in 2011 was acquired by DanDrit in April 2016.. OncoSynergy has raised $26.71 million across 7 funding rounds from investors including HHS, National Cancer Institute and KICC. The company has 3 employees as of December 31, 2021. OncoSynergy offers products and services including OS2966 and Therapeutic Platforms. OncoSynergy operates in a competitive market with competitors including Harbour BioMed, Xilio Therapeutics, Zymeworks, Lassen Therapeutics and Ambrx, among others.
- Headquarter San Francisco, United States
- Employees 3 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Oncosynergy, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OncoSynergy
OncoSynergy offers a comprehensive portfolio of products and services, including OS2966 and Therapeutic Platforms. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Antibody that blocks receptors to inhibit cancer growth and resistance
Platforms for developing treatments against various solid and hematological cancers
Unlock access to complete
Unlock access to complete
Funding Insights of OncoSynergy
OncoSynergy has successfully raised a total of $26.71M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $3.45 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series A — $3.5M
-
First Round
First Round
(04 May 2018)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2022 | Amount | Series A - OncoSynergy | Valuation |
investors |
|
| Nov, 2020 | Amount | Debt – Conventional - OncoSynergy | Valuation |
investors |
|
| Sep, 2020 | Amount | Series A - OncoSynergy | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OncoSynergy
OncoSynergy has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, National Cancer Institute and KICC. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Cancer research is conducted and supported by the institute.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OncoSynergy
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - OncoSynergy
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Oncosynergy Comparisons
Competitors of OncoSynergy
OncoSynergy operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Harbour BioMed, Xilio Therapeutics, Zymeworks, Lassen Therapeutics and Ambrx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody therapeutics are developed for immunology and oncology diseases.
|
|
| domain | founded_year | HQ Location |
Tumor-selective immunotherapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Bi-specific antibodies and antibody-drug conjugates are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biotherapeutics targeting cancer via interleukin-11 are developed.
|
|
| domain | founded_year | HQ Location |
Antibody-drug conjugates are developed for cancers and metabolic disorders.
|
|
| domain | founded_year | HQ Location |
Antibody therapeutics for anti-cancer immune responses are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Oncosynergy
Frequently Asked Questions about OncoSynergy
When was OncoSynergy founded?
OncoSynergy was founded in 2011 and raised its 1st funding round 7 years after it was founded.
Where is OncoSynergy located?
OncoSynergy is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is OncoSynergy a funded company?
OncoSynergy is a funded company, having raised a total of $26.71M across 7 funding rounds to date. The company's 1st funding round was a Series A of $3.25M, raised on May 04, 2018.
How many employees does OncoSynergy have?
As of Dec 31, 2021, the latest employee count at OncoSynergy is 3.
What does OncoSynergy do?
OncoSynergy was founded in 2011 and is based in San Francisco, United States. Inhibitors targeting resistance mechanisms in cancer are developed by the company within the oncology sector. Multiple hallmarks of cancer progression are addressed, with efficacy shown in monotherapy and combinations. The lead program, OS2966, consists of a therapeutic antibody that blocks a cell surface receptor, aimed at treating glioblastoma, ovarian cancer, pancreatic cancer, and malignant meningioma.
Who are the top competitors of OncoSynergy?
OncoSynergy's top competitors include Xilio Therapeutics, Ambrx and Harbour BioMed.
What products or services does OncoSynergy offer?
OncoSynergy offers OS2966 and Therapeutic Platforms.
Who are OncoSynergy's investors?
OncoSynergy has 6 investors. Key investors include HHS, National Cancer Institute, KICC, Connecticut Innovations, and Navation.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.